JPRN-UMIN000012452已完成2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab Therapy - Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab Therapy (CYBORG-002)
Chiba Youth Breast Oncology Research Group (CYBORG)0 个研究点目标入组 35 人开始时间: 2013年12月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients who have an active infection or high fever with suspicious infection. 2. Patients who have a history of cardiac disease, including known symptomatic decreases in LVEF to less than 50% absolute value during prior trastuzumab therapy or congestive heart failure. 3. Patients with pulmonary fibrosis or interstitial pneumonia that is clear from the chest X-ray 4. Patients with previous exposure to a cumulative dose of doxorubicin of more than 360 mg/m2 5. Patients with a decline in LVEF to less than 50% during or after former trastuzumab treatment 6. Patients suspected of being pregnant or pregnant women 7. Patients with another malignancy within the last 5 years 8. Patients with uncontrollable brain metastases 9. Patients who were considered by the primary care physician to be inappropriate as subjects of this trial
研究者
相似试验
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
暂停
不适用
Phase II trial of pertuzumab and trastuzumab in combination with S-1 for patients with HER2-positive metastatic breast cancerBreast cancerJPRN-UMIN000024477Kurume University School of Medicine32
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45